ArticleBlood advances2017

TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.

Hirofumi Tenshin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.